- Home
- GLPG
GLPG
Galapagos NV
as of 12-10-2025 12:13pm EST
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
| Founded: | 1999 | Country: | Belgium |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.1B | IPO Year: | 2005 |
| Target Price: | $31.33 | AVG Volume (30 days): | 112.6K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.36 - $37.78 | Next Earning Date: | 11-05-2025 |
| Revenue: | $336,643,201 | Revenue Growth: | 10.31% |
| Revenue Growth (this year): | 3.61% | Revenue Growth (next year): | -1.30% |
AI-Powered GLPG Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare GLPG vs Leading Stocks
See how GLPG stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GLPG Galapagos NV - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.